Multidisciplinary focus on cyclosporin a

Carlo Salvarani, Luigi Boiardi, Pierluigi Macchioni, Nicolò Pipitone, Mariagrazia Catanoso, Paolo Pigatto

Research output: Contribution to journalArticlepeer-review


Cyclosporin A (CsA) has been proved to be effective in the treatment of severe cutaneous psoriasis and psoriatic arthritis (PsA). In psoriasis, CsA therapy can be used as: (1) intermittent short-course therapy; (2) continuous longterm therapy; (3) crisis intervention; and (4) a combination of sequential and rotational therapy. Several open prospective studies have shown the short-term efficacy of CsA in PsA. While there were no randomized controlled trials (RCT) comparing CsA to placebo, 3 published controlled trials compared CsA to other disease modifying antirheumatic drugs (DMARD). These studies support the efficacy of CsA in patients with PsA and peripheral arthritis. However, no conclusions can be drawn on the efficacy of CsA for dactylitis and axial disease. Longterm studies have shown the persistent efficacy and safety of CsA in PsA. The beneficial effects of CsA in angiogenesis-related diseases such as PsA and cutaneous psoriasis may also be mediated by its ability to block the angiogenic effects induced by vascular endothelial growth factor.

Original languageEnglish
Pages (from-to)52-55
Number of pages4
JournalJournal of Rheumatology
Issue numberSUPPL. 83
Publication statusPublished - Aug 2009


  • Cyclosporin A
  • Psoriasis
  • Psoriatic arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)


Dive into the research topics of 'Multidisciplinary focus on cyclosporin a'. Together they form a unique fingerprint.

Cite this